운전자본 팽창 → 현금 고갈 → 유동성 위기
Warning순운전자본이 +20.1% 팽창하며 현금이 묶이고 있다. 영업CF/순이익 비율이 -16%로 이익 대비 현금 회수가 부족하고, 유동비율도 3.40에서 3.04로 하락했다.
Evidence
순운전자본 YoY +20.1%영업CF/순이익 -16%유동비율 3.40→3.04
GeneBioTech Co. ,Ltd
A086060 · KOSDAQ₩4,700+0.75%
2026-08-25 closeGeneBioTech Co. ,Ltd — pricey right now, or cheap? And what signals are flashing today?
The grade and valuation bands are below — free to read.
Loading chart…
Close
AI Insight
Why these signals fired — only backtest-proven edge, told honestly
New high + volume — the real recordrecord · not a prediction
Not this one stock, but every new-high-plus-volume pick we actually published (Korea market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-25)
Last 30 sessions
402 picks
Next-day win rate
51.6%
Avg next-day
-0.06%
vs market
-0.24%p
Beat the market on 45.3% of picks (each pick vs its own day’s market average).
Recent publish days (next-day win rate)
08-23 60%08-21 36.4%08-20 44.4%08-19 0%08-18 27.3%08-14 23.1%08-13 41.7%08-12 70%08-11 77.8%08-10 22.2%08-07 61.5%08-06 27.3%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.
Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.
Trade plan
Decide the exit before you enter. Set what you are willing to lose first, and the share count follows — so you know the worst case before you buy.
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
This is a calculator, not advice, and it does not promise any outcome. You choose the stop and target — the button values (ATR, recent low/high) are observations from past prices. Actual fills depend on the order book and liquidity.
Valuation Grades
Relative to 291 건강관리 peers · not investment advice
A-
Overall: 건강관리 69/291 · top 23%
Factor composite · relative position in sector
Valuation in its own history
PER 14.12 · PBR 0.79 — own history (2006-04~) percentiles 83/100 · 72/100
PER83/100
PBR72/100
Higher indicates lower valuation relative to its history (based on earnings and book yields).
Earnings percentiles can fluctuate for cyclical companies (including loss periods), so the book basis is shown alongside. Companies with large share buybacks can have structurally high PBR. Factual information, not investment advice.
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 7.76
Distress
Grey
Safe
- Altman Z''
- 7.76
- Beneish M-Score
- -2.12
- Sloan accrual
- 4.62%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Why has this company moved this way?
Auditable observations with the original numeric evidence.
매출 성장 + 마진 확대 + FCF 양수
Positive매출이 +4.4% 성장하면서 영업이익률이 4.2%에서 4.6%로 확대되었다. FCF도 양수를 유지하여 질적 성장이 확인된다.
Evidence
매출 YoY +4.4%영업이익률 4.2%→4.6%FCF 719
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
3/9Weak
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score3/9
Profitability
- Positive ROAPass
- Positive OCFNot passed
- Improving ΔROAPass
- Accruals (OCF > net income)Not passed
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesPass
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Industry structure
KRAs of 2026-08-25건강관리
This stock is in 건강관리: revenue rank 133 of 287, share 0.1%.
133 / 2870.1%revenue share
Who dominates this industry?
- 1삼성바이오로직스7.3%
- 2셀트리온5.7%
- 3녹십자홀딩스3.5%
- 4유한양행3.3%
- 5대웅3.1%
- 6진바이오텍0.1%
Concentration
DistributedCR3 16.6%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
Winner-take-all deepeningConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 31.61
- Direction
- 확대
- Level
- 넓음
- Years
- 7
Value lens
- P90/P10
- 14
- Median P/B
- 1.47
- Level
- 넓음
- n
- 263
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- 4.6%
- Interest coverage
- 6x
- Return on equity (ROE)
- 5.6%
Operating margin −5pp
Operating lossInterest coverageBase 6x adverse case -0.5x
Return on equity (ROE)Base 5.6% adverse case -1.9%
Revenue −15%
TolerableInterest coverageBase 6x adverse case 5.1x
Return on equity (ROE)Base 5.6% adverse case 5.1%
Interest rate +2pp
TolerableInterest coverageBase 6x adverse case 3.6x
Return on equity (ROE)Base 5.6% adverse case 5.5%
Interest coverage limit
Current margin 3.9ppInterest coverage limit at an operating margin of 0.8%
Interest expense coverage threshold
Key suppliers · Annual report
Annual reportDART · 2026-03-18Suppliers disclosed by the company in its 2026-03-18 annual report.
Purchase amount
KRW 100m- CuSOKRW 667T
- 다원케미칼본사KRW 953.8B
Suppliers without disclosed amount
진바이오텍본사진바이오텍은다원케미칼은VITAMINNIACINBatch
Financials at a glance
GeneBioTech Co. ,Ltd's latest results and balance sheet. The bars track the last three periods.
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 김성호19.40%2026-08-10 · 증감 +1.10%p
Other stocks held by the same investors
A filing-based shared-holder record, not investment advice.
- 이지스KRA261520 →
Shared holders: 김성호
Connections
AI-extracted related companies · for reference
Suppliers
노바티스DSM-Firmenich
Customers
Competitors
Same theme
사료첨가제
Recent filings
GeneBioTech Co. ,Ltd's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
Signal history (last ~2 years)
Every occurrence on this stock, with the return 20 trading days later. Small sample — a record, not a prediction.
Golden cross×1
26-08-03·
“·” = fewer than 20 trading days since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.
Like these rules? Run them automatically.
Quantus turns rules like these into backtests and automated trading — same team, free to start.
Quantus Signal · live data · not investment advice · Privacy Policy